AND TEMPUS Genomic Testing Program

Your Tumor's DNA / RNA Can Help Identify the Best Treatment Option(s) Available Genomic cancer testing, sometimes referred to as biomarker testing, helps detect changes in a tumor’s DNA—called genomic alterations—that can affect how your cancer grows and spreads. The results of the test can help your doctor create a treatment plan.

Talk to Your Doctor About Genomic Cancer Testing The only way to identify genomic alterations is with genomic cancer testing. This test can reveal information about what may be driving the growth of your colorectal cancer (CRC), such as an NTRK gene fusion.

NTRK Gene Fusions and Colorectal Cancer Cancer may contain an actionable alteration, which is a genomic alteration that NTRK Gene and Unrelated Gene your doctor can act on with approved treatment(s) or a drug(s) in a clinical trial. One of the actionable alterations included in the test is an NTRK gene fusion.

NTRK gene fusions can be found in that form in many parts of the body, NTRK and including the colon. When an NTRK gene joins—or fuses—with a different, Unrelated Genes Break and Join unrelated gene, it can cause cancer cells to multiply.

Some patients with metastatic colorectal cancer exhibit MicroSatellite Instability (MSI). High MSI (MSI-H) results from defects in the way cells repair NTRK Gene Fusion their DNA as they divide.

NTRK gene fusions are more prevalent among MSI-H CRC cases Studies suggest NTRK gene fusions are found in a range of 0.2% to 2.7% of all colorectal cancer cases and in approximately 5% of MSI-H CRC cases.

Bayer is Sponsoring a Genomic Cancer Test (Tempus xT) for Eligible CRC Patients at NO COST Bayer is collaborating with Tempus in offering Tempus xT, a broad genomic test that detects actionable alterations, including NTRK gene fusions, for eligible mCRC patients with confirmed MSI-H status.

Bayer will cover the cost of the xT test regardless of the results, treatment decision or insurance coverage Just Three Easy Steps to Enroll

Download the Test Speak with your doctor Based on the results, your Requisition Form at and request to get tested at doctor will discuss appropriate Tempus.com/bayerprogram NO COST if you are eligible treatment options with you

© 2020 Bayer. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer. 12/2020 | PP-PF-ONC-US-1610-1 microsatellite instability(MSI-H). (mCRC), talktoyourdoctorfind outifyouhavehigh If youhave beendiagnosedwithmetastaticcolorectalcancer How doIknowifhaveMSI-HmCRC? ABOUT ABOUT THE BAYER AND TEMPUS ABOUT GENOMIC NEXT STEPS GENOMIC CANCER TESTING PROGRAM CANCER TESTING Meet withyourdoctortodiscuss thepotential treatmentoptionsbased onthetestresults. My doctorsubmitted thetestandreceivedreport.Now what? results within14days. Once yourdoctorsubmitstumorsampleandregistration formtoTempus,yourdoctorwillreceivethe How longwillittaketogetmyresults? NO COSTfortheTempusxTtestunder thisprogram. Any mCRCpatient withMSI-Hiseligibletoparticipateintheprogram regardlessofinsurancecoverage.Therewillbe What ifIdon’thavehealthinsurance?Willbefinanciallyresponsibleforthis? Please talktoyourdoctorlearnmoreabouteligibilityreceiveagenomiccancertestatNOCOST. Who shouldIcontacttoparticipateinthisprogram? alternate orfuturetreatmentoptions.Youshoulddiscuss nextstepswithyourdoctor. Yes, genomiccancertestingisstillrelevantbecause understanding yourtumor'sgenomicprofilemayinformdoctorof Is thisrelevantformeifIamalreadyreceivingtreatment? to generationbased onaspecificsetofgenes andtypicallyinvolvesgeneticcounseling. . Bycontrast,genetic testinglooksatinheritedtraitsordiseaserisksthatmaybepasseddownfromgeneration Genomic cancertestinghelps identifywhat maybe drivingyourtumortogrowandspreadbylookingatentire What isthedifferencebetweengenetictestingandgenomiccancertesting? covers thefullcostofTempusxTtest. program butshouldworkwiththeirdoctortocollectthetumorsampleandcoverassociatedcosts.ThisONLY tumor iseligibletoenrollintheprogram. Patientswhohavenotpreviously undergoneabiopsymaystillenrollinthe Any U.S.metastaticcolorectalcancer(mCRC)patientwithhighmicrosatelliteinstability(MSI-H)andapreviouslybiopsied Am Ieligibleforthetestingprogram? © 2020Bayer. Allrightsreserved. Bayerand the BayerCrossare registeredtrademarks ofBayer.12/2020 |PP-PF-ONC-US-1610-1 Learn more… Why shouldIconsideragenomiccancertest? cancer testmaybe rightforyouoralovedone. trial. Askyourdoctorabouteligibilityandwhetheragenomic matched toeitheranapprovedtherapyoradrug inaclinical alterations inyourtumor,whichmeansthattheycouldbe Genomic cancertestingisthebestmethodtouncoveractionable